| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e4790c814adc8c5a88802341d396009 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-72 |
| filingDate |
2016-07-29^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ea1a5a7d0ca51b737d431a485f6f65a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3409b40ccbd5f47cba8c6a04fdfc549 |
| publicationDate |
2017-02-09^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20170015848-A |
| titleOfInvention |
Novel compound having tumor diagnosis or tumor growth inhibitory activity on EGFR mutant and medical uses comprising the same |
| abstract |
The present invention relates to a novel compound or a salt thereof having tumor growth and growth inhibitory activity with epithelial cell growth factor receptor mutants, a contrast agent containing the same, and a pharmaceutical composition for treating or preventing EGFR-related cancer diseases containing the same as an active ingredient The novel compound or its salt according to the present invention can selectively inhibit the EGFR mutant without inhibiting the wild-type EGFR, and thus can treat and prevent lung cancer, colon cancer or breast cancer which is an EGFR-related cancer disease. Especially, Can effectively treat and prevent non-small cell lung cancer. In addition, the novel compounds or salts thereof according to the present invention target tumor response to EGFR mutation-inducing cancer cells or EGFR T790M mutation-inducing cancer cells through EGFR mutation rather than wild-type EGFR-overexpressing cancer cells, And can be used as a contrast agent that can be distinguished. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200045666-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253516-B2 |
| priorityDate |
2015-07-31^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |